Email

arpit.rao@bcm.edu

Addresses

Alkek Building for Biomedical Research ( (Lab)

Professional Statement

Dr. Arpit Rao is an Associate Professor of Hematology and Oncology, and the Chair of the Prostate Cancer Program at the Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine.

Dr. Rao was previously a faculty member at the University of Minnesota, where he held several leadership roles including the GU Oncology Research Chair at the Masonic Comprehensive Cancer Center, and the Director of Quality and Safety for the oncology service line. He served as the institutional PI for over 30 clinical trials, spanning all phases of drug development and in multiple disease settings. He has played an important role in the FDA approval of multiple new treatment options for cancer patients in the recent years.

Dr. Rao’s research is funded by the U.S. National Cancer Institute (NCI), Alliance for Clinical Trials in Oncology, Prostate Cancer Foundation, Department of Defense, several pharmaceutical companies, and community non-profit organizations. In addition to being the Principal Investigator (Study Chair) for CASPAR, an NCI-funded, 1002-patient phase 3 clinical trial of enzalutamide and rucaparib in first line metastatic castration-resistant prostate cancer (mCRPC); Dr. Rao is also leading an industry-sponsored phase 2 trial of abemaciclib and atezolizumab in mCRPC.

He has advised on the global clinical and translational development programs of abemaciclib and rucaparib in prostate cancer and served on DSMB for several large industry-sponsored studies.

Dr. Rao's expertise in genitourinary malignancies is globally recognized and he currently treats patients with prostate, kidney, bladder, and testicular cancer in his clinic at the Dan L. Duncan Comprehensive Cancer Center.